CP-023 Use of intravitreal antiangiogenic drug in a large study in the treatment of retinopathy of prematurity

BackgroundRetinopathy of prematurity (ROP) is a proliferative disease of the retinal vasculature that can cause severe visual loss in premature newborns. Intravitreal bevacizumab has shown promise as a treatment for ROP.PurposeTo evaluate the efficacy and safety of intravitreal bevacizumab in preter...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A10-A10
Main Authors: Fernández-Ginés, FD, Rodríguez-Cuadros, TB, Paz, S Cañizares, Molina-Cuadrado, E
Format: Article
Language:English
Subjects:
Gestational age
Patients
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundRetinopathy of prematurity (ROP) is a proliferative disease of the retinal vasculature that can cause severe visual loss in premature newborns. Intravitreal bevacizumab has shown promise as a treatment for ROP.PurposeTo evaluate the efficacy and safety of intravitreal bevacizumab in preterm infants with retinopathy diagnosed with grades 1–3+.Material and methodsThis was a retrospective study of 24 months’ duration involving patients less than 30 weeks’ gestational age diagnosed with ROP to grade 3+ and weighing
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2017-000640.22